The invention provided herein a pharmaceutical process used for an extraction of proteins from pancreatic sample and estimation of the extracted proteins. Moreover, the invention provides a use of suitable is selected from citrate-phosphate buffer and bicarbonate buffer capable to extract proteins from pancreatic sample. The invention further provides an analytical method to perform estimation of extracted proteins. This process provides an improved extraction method to quantify protein present in the pancreatic sample.

The present invention provides an improved method for analysis of pancreatic protein mixture comprises at least more than one biological active protein selected from amylase, protease and lipase, wherein the analysis and quantification of pancreatic protein mixtures is performed with Size Exclusion High Performance Liquid Chromatography (SE-HPLC). Also, the present invention provides the process for the separation, analysis and quantification of low molecular weight and high molecular weight enzymes present in pancreatic protein mixture.

Provided is a process for producing a substrate solution for measuring lipase activity including, as a substrate for measuring lipase activity, 1,2-o-dilauryl-rac-glycero-3-glutaric acid (6-methylresorufin) ester, wherein the production process does not necessitate cumbersome or special processing such that skill is required, or does not necessitate a special apparatus, instruments, or other items. This production process is a process for producing a substrate solution for measuring lipase activity, and is characterized by including the steps of (1) mixing the substrate for measuring lipase activity and a side-chain-type nonreactive polyether-modified-type modified silicone oil or a polyoxyethylene/polyoxypropylene condensate to prepare a mixture, and (2) mixing all or a portion of the mixture of step (1) with water or an aqueous solution.

The present invention provides methods for quantifying an amount of plasmalogens in samples with high accuracy in an easy, convenient and inexpensive manner by using a hydrolysis processing to samples and a lipid extraction followed by the measurement using High Performance Liquid Chromatography (HPLC) with Evaporative Light Scattering Detector (ELSD) or Mass Spectrometer (MS), a fluorescence plate reader or a plate reader. The present invention also relates to a method for examining a subject by using the above method, a biomarker for disease detection, a method for using the biomarker for the disease detection, as well as a kit for the disease detection.

Use of at least one chromogenic and/or fluorogenic carboxylesterase and/or triacylglycerol-lipase substrate, to detect bacteria of the Bacillus cereus group in a sample capable of containing them.

The present invention provides methods for quantifying an amount of plasmalogens in samples with high accuracy in an easy, convenient and inexpensive manner by using a hydrolysis processing to samples and a lipid extraction followed by the measurement using High Performance Liquid Chromatography (HPLC) with Evaporative Light Scattering Detector (ELSD) or Mass Spectrometer (MS), a fluorescence plate reader or a plate reader. The present invention also relates to a method for examining a subject by using the above method, a biomarker for disease detection, a method for using the biomarker for the disease detection, as well as a kit for the disease detection.

Provided is a method of avoiding the influence of a coexisting substance in the measurement of HbA1c % for a whole blood sample by an enzymatic method. Specifically, provided is a method of measuring a ratio of a hemoglobin A1c concentration to a hemoglobin concentration in a sample by an enzymatic method, the method including: a first step of optically measuring the hemoglobin concentration; and a second step of optically measuring the hemoglobin A1c concentration, wherein, when HbA1c % is calculated by dividing the hemoglobin A1c concentration measured in the second step by the hemoglobin concentration measured in the first step, the hemoglobin concentration serving as a denominator, which is measured at a first wavelength, is corrected using a result measured at a second wavelength.

Disclosed a system (100) for enacting a positive and a negative pressure on a limb. The system (100) includes an air compressor (102) coupled to a reservoir (104), a piston assembly (106) configured to the reservoir (104), wherein the piston assembly (106) further comprises a piston (108) circumfused inside a tube (107), a pneumatic ring (114) coupled to the system (100) via the piston assembly (106) maintains intermittent pressure and prevents formation of a venous blood clot ischemic injury to a tissue distal to the pneumatic ring (114) compression due to lack of blood flow.

A method of treatment for congestive colon failure (CCF) including evaluating an origin of a lipase and/or an amylase from a biological fluid sample from the subject, optionally analyzing a level of the lipase and/or an amylase from the biological fluid sample from the subject, optionally imaging a colon and a pancreas of the subject and providing laxatives, an anti-fungal composition, fat, a composition selected from a group comprising glucosamine, methylsulfonylmethane (MSM) rhamnan sulfate, Sulodexide, Rosuvastatin, Metformin, Hydrocortisone, Antithrombin, Etanercept, Heparin, Albumin, Fresh frozen plasma (FFP), Poloxamer-188, vitamins, trace elements, a locally acting vasodilator, anaerobic microbial culture, pickled fruits, pickled vegetables, preserved meat, and fermented juices or a combination thereof based upon results of the first three steps.

Provided is a compound having the structure:

(SIG)-(SI-MOD).sub.m

where SIG is a signaling molecule, SI is a self-immolative structure bound to SIG such that SIG has a reduced signal relative to the signal of SIG without SI, MOD is a moiety bound to SI that is subject to modification by an activator, and m is an integer from 1 to about 10. When MOD is modified by an activator, SI is destabilized and self-cleaved from SIG such that SIG generates an increased signal. Also provided are methods of determining whether a sample, such as a cell, comprises an activator, such as a nitroreducase, using the compound. Further provided are methods of determining whether a mammalian cell is hypoxic using the compound where nitroreductase is the activator. A method of detecting a microorganism that comprises a nitroreductase using the compound where nitroreductase is the activator is also provided.